Citadel Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-18,900
| Closed | -$976K | – | 16024 |
|
|
2022
Q3 | $976K | Sell |
18,900
-27,000
| -59% | -$1.12M | ﹤0.01% | 7048 |
|
|
2022
Q2 | $1.14M | Sell |
45,900
-95,000
| -67% | -$2.09M | ﹤0.01% | 6736 |
|
|
2022
Q1 | $3.53M | Sell |
140,900
-24,900
| -15% | -$700K | ﹤0.01% | 4850 |
|
|
2021
Q4 | $6.04M | Sell |
165,800
-38,700
| -19% | -$1.36M | ﹤0.01% | 3970 |
|
|
2021
Q3 | $3.5M | Buy |
204,500
+28,700
| +16% | +$447K | ﹤0.01% | 5031 |
|
|
2021
Q2 | $2.35M | Buy |
175,800
+155,300
| +758% | +$3.83M | ﹤0.01% | 6193 |
|
|
2021
Q1 | $1.05M | Buy |
20,500
+800
| +4% | +$48.1K | ﹤0.01% | 7990 |
|
|
2020
Q4 | $1.22M | Sell |
19,700
-28,900
| -59% | -$1.65M | ﹤0.01% | 6378 |
|
|
2020
Q3 | $2.66M | Buy |
48,600
+28,700
| +144% | +$1.55M | ﹤0.01% | 4193 |
|
|
2020
Q2 | $1.15M | Sell |
19,900
-8,800
| -31% | -$479K | ﹤0.01% | 5584 |
|
|
2020
Q1 | $1.15M | Sell |
28,700
-25,600
| -47% | -$1.09M | ﹤0.01% | 5078 |
|
|
2019
Q4 | $2.15M | Buy |
54,300
+36,600
| +207% | +$643K | ﹤0.01% | 4304 |
|
|
2019
Q3 | $120K | Buy |
17,700
+200
| +1% | +$1.5K | ﹤0.01% | 8398 |
|
|
2019
Q2 | $163K | Sell |
17,500
-9,000
| -34% | -$104K | ﹤0.01% | 8321 |
|
|
2019
Q1 | $368K | Buy |
26,500
+400
| +2% | +$4.57K | ﹤0.01% | 7302 |
|
|
2018
Q4 | $285K | Buy |
26,100
+7,200
| +38% | +$75.9K | ﹤0.01% | 7360 |
|
|
2018
Q3 | $239K | Buy |
+18,900
| New | +$228K | ﹤0.01% | 7957 |
|
|
2018
Q2 | – | Sell |
-12,000
| Closed | -$163K | – | 9450 |
|
|
2018
Q1 | $163K | Sell |
12,000
-1,000
| -8% | -$10.3K | ﹤0.01% | 7491 |
|
|
2017
Q4 | $77K | Buy |
+13,000
| New | +$89.2K | ﹤0.01% | 7508 |
|
|
2016
Q1 | – | Sell |
-3,400
| Closed | -$28K | – | 8327 |
|
|
2015
Q4 | $28K | Buy |
+3,400
| New | +$24.1K | ﹤0.01% | 7720 |
|
|
2014
Q3 | – | Sell |
-800
| Closed | -$5K | – | 8514 |
|
|
2014
Q2 | $5K | Buy |
+800
| New | +$4.49K | ﹤0.01% | 7733 |
|
Other funds holding CCXI
Citadel Advisors's CCXI Position: Q4 2022 in Review
Citadel Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 112,981 shares — an estimated $5.84M sold.
Citadel Advisors first reported a position in CCXI in Q2 2014 and held it in 27 quarters. The position peaked at $43.6M in Q2 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Citadel Advisors reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 112,981 ChemoCentryx, Inc. shares in Q4 2022, an estimated $5.84M.
- Citadel Advisors first reported a position in ChemoCentryx, Inc. in Q2 2014 and held it in 27 quarters.
- Citadel Advisors's ChemoCentryx, Inc. position peaked at $43.6M in Q2 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.